The Future of Clinical Research in Generic Drug Development

The generic pharmaceutical industry is at a critical juncture. Traditionally, the route to market for generics involved proving bioequivalence via pharmacokinetic studies in healthy volunteers, compiling data, and submitting an Abbreviated New Drug Application (ANDA). This established process was aimed at ensuring predictability rather than accommodating disruption.

That era is ending. The convergence of regulatory evolution, technological innovation, and shifting global dynamics is reshaping the development, testing, and approval of generic drugs. Harmonized bioequivalence standards, integration of artificial intelligence, and decentralized trial models are making the future of clinical research in generics faster, smarter, and more complex.Zenovel provides clinical research services to assist generic manufacturers in adapting to changes in the industry effectively.

The implementation of the ICH M13A guideline in January 2025 marks a significant shift, harmonizing bioequivalence standards for immediate-release solid oral dosage forms such as tablets, capsules, and granules. This guidance, adopted by both the FDA and EMA, has profound implications for generic manufacturers.

M13A marks the initial phase, with the ICH progressing towards M13B, which focuses on additional strengths for biowaivers, and discussions on M13C that will tackle complex bioequivalence studies, particularly for Narrow Therapeutic Index Drugs (NTIDs). The FDA is innovating by prioritizing research that utilizes artificial intelligence for improved decision-making and creating frameworks for virtual bioequivalence, which integrates in silico modeling alongside in vivo and in vitro evidence. These advancements aim to enhance the generic drug process and modernize regulatory frameworks through data science improvements.

AI and Machine Learning in Drug Development

Artificial intelligence has become a current reality in generic drug development, significantly improving efficiency, accuracy, speed, and regulatory compliance through advanced AI-powered tools.

Key applications include:

• Decentralized Clinical Trials

The traditional clinical research model, which necessitates patient visits to centralized sites, is evolving towards more flexible, patient-centric methods. Decentralized Clinical Trials (DCTs) utilize digital tools and innovative operations to minimize or eradicate the need for patient travel to trial sites. They present significant benefits for generic drug development.

Regulatory agencies such as the FDA, EMA, and NMPA are promoting the adoption of DCTs. The European Medicines Regulatory Network has guided the incorporation of decentralized components in clinical studies. For generic manufacturers, DCTs offer a chance to lower costs, expedite timelines, and produce data that better represents real-world product performance.

•  Real-World Evidence:

Real-world evidence (RWE) is becoming crucial in regulatory decision-making. The ICH has started a new topic on “Considerations for the Use of RWE,” involving the EMA, FDA, and Health Canada. For generic products, RWE can enhance traditional bioequivalence studies.

Regulatory acceptance of RWE is increasing, providing a competitive edge to generic manufacturers that incorporate RWE into their development and surveillance initiatives.

• Complex Generics

Complex generics, which include products with intricate active ingredients, formulations, delivery methods, or drug-device combinations, represent the future of the generic industry, building on the foundation of traditional immediate-release oral tablets.

•    These products present significant challenges:

Regulatory bodies recommend systematic, science-based approaches for complex generics, emphasizing accurate and reproducible methods. Manufacturers adept at navigating these complexities can seize substantial market opportunities.

Zenovel combines expertise and global reach to assist generic manufacturers in the evolving market. With extensive industry experience and a presence in key regions like India, the USA, Canada, and the EU, along with service to numerous countries, Zenovel is well-equipped for the future of generic drug development.

• GCP Adherence for effective clinical trials

Zenovel provides comprehensive clinical trial services across all phases (I-IV), including bioequivalence and pharmacokinetic studies, GCP monitoring tasks, and numerous audits and studies completed. Our services feature Risk-Based Monitoring (RBM) for enhanced patient safety and data integrity, PK-Stat Review for regulatory evidence, clinical monitoring to ensure data accuracy and protocol adherence, and pre-inspection readiness to prepare facilities for regulatory compliance.

• Navigating Global Pathways through Regulatory Affairs  

Zenovel’s regulatory team leverages extensive experience in regulatory strategies, encompassing MAA submission, post-approval submissions to regulatory agencies, hands-on knowledge of eCTD software for EU and US submissions, and expertise in dossier review for both regulated and semi-regulated markets, including gap assessments across different markets.

•  GMP Compliance for  Manufacturing Excellence

Zenovel provides GMP expertise to manufacturers, assisting with plant design and regulatory compliance, and conducts audits at sites across India, China, Vietnam, South Korea, Taiwan, Malaysia, Turkey, the USA, Europe, and the UK.

Zenovel combines expertise and global reach to assist generic manufacturers in the evolving market. With extensive industry experience and a presence in key regions like India, the USA, Canada, and the EU, along with service to numerous countries, Zenovel is well-equipped for the future of generic drug development.

Ready to future-proof your generic drug development program?  Today to learn how their comprehensive clinical research services can support your next submission.